Search Results - "White, Kirsten" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

by Tsiang, Manuel, Jones, Gregg S, Goldsmith, Joshua, Mulato, Andrew, Hansen, Derek, Kan, Elaine, Tsai, Luong, Bam, Rujuta A, Stepan, George, Stray, Kirsten M, Niedziela-Majka, Anita, Yant, Stephen R, Yu, Helen, Kukolj, George, Cihlar, Tomas, Lazerwith, Scott E, White, Kirsten L, Jin, Haolun
Published in Antimicrobial agents and chemotherapy (01.12.2016)

Get full text

Journal Article

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

by Andreatta, Kristen, Willkom, Madeleine, Martin, Ross, Chang, Silvia, Wei, Lilian, Liu, Hui, Liu, Ya-Pei, Graham, Hiba, Quirk, Erin, Martin, Hal, White, Kirsten L
Published in Journal of antimicrobial chemotherapy (01.12.2019)

Get full text

Journal Article

MC1R Variation in a New Mexico Population

MC1R Variation in a New Mexico Population

by White, Kirsten A M, Dailey, Yvonne T, Guest, Dolores D, Zielaskowski, Kate, Robers, Erika, Sussman, Andrew, Hunley, Keith, Hughes, Christopher R, Schwartz, Matthew R, Kaphingst, Kimberly A, Buller, David B, Hay, Jennifer L, Berwick, Marianne
Published in Cancer epidemiology, biomarkers & prevention (01.11.2019)

Get full text

Journal Article

Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks

Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks

by Acosta, Rima K, Willkom, Madeleine, Martin, Ross, Chang, Silvia, Wei, Xuelian, Garner, William, Lutz, Justin, Majeed, Sophia, SenGupta, Devi, Martin, Hal, Quirk, Erin, White, Kirsten L
Published in Antimicrobial agents and chemotherapy (01.05.2019)

Get full text

Journal Article

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome

by Abram, Michael E, Ram, Renee R, Margot, Nicolas A, Barnes, Tiffany L, White, Kirsten L, Callebaut, Christian, Miller, Michael D
Published in PloS one (17.02.2017)

Get full text

Journal Article

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

by DeJesus, Edwin, Rockstroh, Jürgen K, MD, Henry, Keith, MD, Molina, Jean-Michel, MD, Gathe, Joseph, MD, Ramanathan, Srinivasan, PhD, Wei, Xuelian, PhD, Yale, Kitty, MSc, Szwarcberg, Javier, MD, White, Kirsten, Prof, Cheng, Andrew K, MD, Kearney, Brian P, Prof
Published in The Lancet (British edition) (30.06.2012)

Get full text

Journal Article

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials

by D'Antoni, Michelle L, Andreatta, Kristen, Acosta, Rima, Martin, Hal, Chang, Silvia, Martin, Ross, White, Kirsten L
Published in Journal of acquired immune deficiency syndromes (1999) (01.04.2022)

Get more information

Journal Article

Antiviral activity of HIV‐1 integrase strand‐transfer inhibitors against mutants with integrase resistance‐associated mutations and their frequency in treatment‐naïve individuals

Antiviral activity of HIV‐1 integrase strand‐transfer inhibitors against mutants with integrase resistance‐associated mutations and their frequency in treatment‐naïve individuals

by Margot, Nicolas A., Ram, Renee R., White, Kirsten L., Abram, Michael E., Callebaut, Christian
Published in Journal of medical virology (01.12.2019)

Get full text

Journal Article

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results

by Zolopa, Andrew, Sax, Paul E, DeJesus, Edwin, Mills, Anthony, Cohen, Calvin, Wohl, David, Gallant, Joel E, Liu, Hui C, Plummer, Andrew, White, Kirsten L, Cheng, Andrew K, Rhee, Martin S, Szwarcberg, Javier
Published in Journal of acquired immune deficiency syndromes (1999) (01.05.2013)

Get more information

Journal Article

Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight

Lack of an association between clinical INSTI-related body weight gain and direct interference with MC4 receptor (MC4R), a key central regulator of body weight

by McMahon, Carrie, Trevaskis, James L, Carter, Christoph, Holsapple, Kevin, White, Kirsten, Das, Moupali, Collins, Sean, Martin, Hal, Burns-Naas, Leigh Ann
Published in PloS one (28.02.2020)

Get full text

Journal Article

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I

by Sax, Paul E, Andreatta, Kristen, Molina, Jean-Michel, Daar, Eric S, Hagins, Debbie, Acosta, Rima, D'Antoni, Michelle L, Chang, Silvia, Martin, Ross, Liu, Hui, Blair, Christiana, McNicholl, Ian, Gallant, Joel, Collins, Sean E, Martin, Hal, White, Kirsten L
Published in AIDS (London) (01.09.2022)

Get full text

Journal Article

Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro

Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro

by Acosta, Rima K, D'Antoni, Michelle L, Mulato, Andrew, Yant, Stephen R, Cihlar, Tomas, White, Kirsten L
Published in Antimicrobial agents and chemotherapy (17.05.2022)

Get full text

Journal Article

Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen

Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen

by Santoro, Maria M., Fornabaio, Chiara, Malena, Marina, Galli, Laura, Poli, Andrea, Menozzi, Marianna, Zazzi, Maurizio, White, Kirsten L., Castagna, Antonella
Published in International journal of antimicrobial agents (01.07.2020)

Get full text

Journal Article

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

by ABRAM, Michael E, HLUHANICH, Rebecca M, SVAROVSKAIA, Evguenia S, MCCOLL, Damian J, WHITE, Kirsten L, MILLER, Michael D, GOODMAN, Derrick D, ANDREATTA, Kristen N, MARGOT, Nicolas A, LINDA YE, NIEDZIELA-MAJKA, Anita, BARNES, Tiffany L, NOVIKOV, Nikolai, XIAOWU CHEN
Published in Antimicrobial Agents and Chemotherapy (01.06.2013)

Get full text

Journal Article

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance

by Acosta, Rima K, Willkom, Madeleine, Andreatta, Kristen, Liu, Hui, Martin, Ross, Parvangada, Aiyappa, Martin, Hal, Collins, Sean, White, Kirsten L
Published in Journal of acquired immune deficiency syndromes (1999) (01.11.2020)

Get more information

Journal Article

Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants

Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants

by Acosta, Rima K, Chen, Grace Q, Chang, Silvia, Martin, Ross, Wang, Xinxin, Huang, Hailin, Brainard, Diana, Collins, Sean E, Martin, Hal, White, Kirsten L
Published in Journal of antimicrobial chemotherapy (15.07.2021)

Get full text

Journal Article

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results

A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results

by Wohl, David A, Cohen, Calvin, Gallant, Joel E, Mills, Anthony, Sax, Paul E, Dejesus, Edwin, Zolopa, Andrew, Liu, Hui C, Plummer, Andrew, White, Kirsten L, Cheng, Andrew K, Rhee, Martin S, Szwarcberg, Javier
Published in Journal of acquired immune deficiency syndromes (1999) (01.03.2014)

Get more information

Journal Article

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial

by Arribas, Jose R, Dr, Pialoux, Gilles, Prof, Gathe, Joseph, MD, Di Perri, Giovanni, Prof, Reynes, Jacques, Prof, Tebas, Pablo, MD, Nguyen, Thai, MD, Ebrahimi, Ramin, MS, White, Kirsten, PhD, Piontkowsky, David, MD
Published in The Lancet infectious diseases (01.07.2014)

Get full text

Journal Article

HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro

HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro

by Andreatta, Kristen, Miller, Michael D, White, Kirsten L
Published in Journal of acquired immune deficiency syndromes (1999) (01.04.2013)

Get more information

Journal Article

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

by Pozniak, Anton, Dr, Markowitz, Martin, Prof, Mills, Anthony, MD, Stellbrink, Hans-Juergen, MD, Antela, Antonio, MD, Domingo, Pere, Prof, Girard, Pierre-Marie, MD, Henry, Keith, Prof, Nguyen, Thai, MD, Piontkowsky, David, MD, Garner, Will, PhD, White, Kirsten, PhD, Guyer, Bill, PharmD
Published in The Lancet infectious diseases (01.07.2014)

Get full text

Journal Article

1
2
3
4
5
6
7
8
Next
[8]